Costco (NASDAQ: COST) is now selling Ozempic and Wegovy at half price, a significant move that could drive new pharmacy customers to its membership-based model. This competitive pricing for popular weight-loss drugs may increase foot traffic and membership renewals for Costco, potentially boosting its retail sales and pharmacy revenue. Investors should monitor the impact of this strategy on Costco's customer acquisition and financial performance.